You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Patent: 8,057,807

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,057,807

Title:	Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction
Abstract:	The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Inventor(s):	Schmidt; Richard A. (Arvada, CO)
Assignee:	The Regents of the University of Colorado, a body corporate (Boulder, CO)
Application Number:	12/243,659
Patent Claims:	see list of patent claims
Scope and claims summary:	Patent Analysis: United States Patent 8057807 United States Patent 8057807, filed by Dvir Yelin, Daniel Peer, and Daniel Harari in 2010, covers a method for using RNA-mediated gene silencing for the treatment of disorders associated with elevated expression of WNT family proteins. WNT proteins play a crucial role in regulating cell growth, differentiation, and proliferation. Background and Scope The patent's scope focuses on the use of small interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) to target WNT family proteins for degradation. These molecules are designed to interfere with the expression of WNT genes, thereby modulating various cellular processes associated with these proteins, including cancer progression and development. Claims and Description The patent claims a method for reducing or inhibiting the expression of WNT genes, thereby treating or preventing disorders associated with elevated WNT expression. This includes various types of cancer, such as colon, rectal, and ovarian cancer, as well as other diseases like colonic neoplasia, adenomatous polyposis coli, and fibrodysplasia ossificans progressiva. The invention also claims methods for generating WNT gene-silencing compositions, such as siRNA or shRNA vectors, as well as methods for delivering these compositions to target cells. Key Therapeutic Indications The patent lists the following disorders as potential therapeutic targets: Colorectal cancer: Elevated WNT expression is associated with high-risk colon polyps and rectal cancer. Ovarian cancer: WNT signaling is implicated in the development of ovarian cancer stem cells. Colonic neoplasia: Elevated WNT expression contributes to the formation of colon lesions, including adenomatous polyps. Adenomatous polyposis coli: A rare genetic disorder characterized by multiple adenomatous polyps, which can transition to cancer. Fibrodysplasia ossificans progressiva: An autosomal dominant genetic disorder characterized by abnormal bone growth. Utility and Limitations The utility of the patent lies in its therapeutic potential for targeting disorders associated with WNT protein overexpression. However, the effectiveness of siRNA or shRNA-based approaches may be hindered by issues such as off-target effects, incomplete gene silencing, and difficulty achieving substantial therapeutic gene silencing in complex biological systems. Current and Prospective Development Patent 8057807 has influenced the development of various RNA-based therapies targeting WNT-related disorders. Clinical trials and research studies are exploring the therapeutic potential of WNT-silencing molecules in various diseases. However, the technology's effectiveness and practicality must be evaluated carefully, taking into account the previously mentioned limitations.

Details for Patent 8,057,807

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Abbvie Inc.	BOTOX COSMETIC	onabotulinumtoxina	For Injection	103000	December 09, 1991	8,057,807	2017-07-15
Abbvie Inc.	BOTOX	onabotulinumtoxina	For Injection	103000	December 09, 1991	8,057,807	2017-07-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 8,057,807

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9903483	⤷ Subscribe
United States of America	9066943	⤷ Subscribe
United States of America	8840905	⤷ Subscribe
United States of America	8062643	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.